Arbutus Biopharma Corp
ABUS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001447028
No open-market purchases or sales by Arbutus Biopharma Corp insiders were filed in the last 90 days; 176 institutions reported holding it in 13F filings for Q2 2026, worth $674.9M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $594.8M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +11 vs. previous quarter
- 176
- 13F valueReported value at the end of Q2 2026
- $674.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $14.1M
- +128.2% year over year
- Net income, FY2025
- -$33.5M
- No comparable prior period
- Free cash flow, FY2025
- -$39.6M
- No comparable prior period
- Revenue, Q3 FY2026
- $299.0K
- −43.5% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $33.5M (237.9% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 19.9M
- Shares sold short
- Change
- −4.68M
- −19.0% vs. previous
- Days to cover
- 9.14
- At average daily volume
Superinvestors holding ABUS, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ABUS at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Arbutus Biopharma Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2025 (view filing) | Feb 4 | 1 day | Hastings David CChief Financial Officer | SSale | −22.2K | $3.28 | −$72.8K | −12.2%159.7K after | 10b5-1 |
| Feb 5, 2025 (view filing) | Feb 4 | 1 day | Sims KarenChief Medical Officer | SSale | −19.3K | $3.28 | −$63.5K | −15.4%106.2K after | 10b5-1 |
| Feb 5, 2025 (view filing) | Feb 4 | 1 day | McElhaugh Michael J.Interim President & CEO | SSale | −23.8K | $3.28 | −$78.0K | −1.6%1.48M after | 10b5-1 |
| Feb 5, 2025 (view filing) | Feb 4 | 1 day | Naftzger J. ChristopherGeneral Counsel and CCO | SSale | −11.3K | $3.28 | −$37.2K | −11.6%86.2K after | 10b5-1 |
| Aug 16, 2024 (view filing) | Aug 14 | 2 days | Manchester Keith SDirector | SSale | −8.85K | $3.69 | −$32.6K | −16.1%46.1K after | |
| Feb 5, 2024 (view filing) | Feb 2 | 3 days | Sims KarenChief Medical Officer | SSale | −4.36K | $2.31 | −$10.1K | −3.4%125.5K after | 10b5-1 |
| Feb 5, 2024 (view filing) | Feb 2 | 3 days | Hastings David CChief Financial Officer | SSale | −9.59K | $2.31 | −$22.2K | −5.0%181.9K after | 10b5-1 |
| Feb 5, 2024 (view filing) | Feb 2 | 3 days | Sofia Michael J.Chief Scientific Officer | SSale | −9.98K | $2.31 | −$23.1K | −0.7%1.49M after | 10b5-1 |
| Feb 5, 2024 (view filing) | Feb 2 | 3 days | McElhaugh Michael J.Interim President & CEO | SSale | −10.2K | $2.31 | −$23.5K | −0.7%1.50M after | 10b5-1 |
| Dec 3, 2021 (view filing) | Dec 1 | 2 days | Sofia Michael J.Chief Scientific Officer | SSale | −200.0K | $5.09 | −$1.02M | −13.3%1.30M after |
Top 10 13F holders, Q2 2026
See all 176 holdersThe largest institutional positions in Arbutus Biopharma Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Two Seas Capital LP | 19,095,583 | $91.7M | 3.50% | +538,040+2.9% | Added |
| Morgan Stanley | 17,698,305 | $85.0M | 0.00% | −8,193,175−31.6% | Reduced |
| Whitefort Capital Management, LP | 15,794,261 | $75.8M | 18.69% | +863,376+5.8% | Added |
| BlackRock, Inc. | 13,766,071 | $66.1M | 0.00% | +799,125+6.2% | Added |
| State Street Corp | 7,869,179 | $37.8M | 0.00% | +1,526,669+24.1% | Added |
| Rubric Capital Management LP | 7,532,937 | $36.2M | 0.33% | +906,548+13.7% | Added |
| Vanguard Capital Management LLC | 7,010,679 | $33.7M | 0.00% | +321,768+4.8% | Added |
| Barclays PLC | 4,207,914 | $20.2M | 0.01% | −108,181−2.5% | Reduced |
| Geode Capital Management, LLC | 4,117,691 | $19.8M | 0.00% | +345,885+9.2% | Added |
| Goldman Sachs Group Inc | 3,506,802 | $16.8M | 0.00% | +2,406,368+218.7% | Added |
Holders of 5% or more of ABUS
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Arbutus Biopharma Corp.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | 13D/A | 19.50%29.9M shares | −1.00 ppfrom 20.50% | Oct 20, 20214 filings | Oct 5, 2026 | SEC |
| Morgan Stanley | 13G/A | 12.20%18.7M shares | +3.40 ppfrom 8.80% | Feb 10, 20216 filings | Oct 7, 2026 | SEC |
| Two Seas Capital LP | 13G/A | 9.40%18.6M shares | +2.90 ppfrom 6.50% | Nov 21, 20236 filings | May 15, 2026 | SEC |
| Whitefort Capital Management, LP | 13G | 8.00%15.8M shares | 0.00 ppfrom 8.00% | Sep 11, 20238 filings | Sep 4, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.20%14.3M shares | – | Oct 27, 20261 filing | Oct 27, 2026 | SEC |